Skip to search formSkip to main contentSkip to account menu

CC-292

Known as: Bruton's Tyrosine Kinase Inhibitor CC-292 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Introduction Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK… 
2017
2017
Correlating target engagement with in vivo drug activity remains a central challenge in efforts to improve the efficiency of drug… 
2017
2017
Ibrutinib is a first-in-class covalent inhibitor of Bruton tyrosine kinase (BTK) approved in the European Union and USA for the… 
Highly Cited
2016
Highly Cited
2016
B-cell receptor (BCR) signaling plays a key role in the pathogenesis of B-cell malignancies, mediating the survival and… 
Highly Cited
2016
Highly Cited
2016
Additions of cysteine thiols to Michael acceptors underpin the mechanism of action of several covalent drugs (e.g., afatinib… 
2015
2015
Ibrutinib, a first generation Btk inhibitor, is approved for the treatment of CLL and mantle cell lymphoma; known toxicities… 
2014
2014
Bruton’s tyrosine kinase (Btk) modulates B-cell development and activation and has an important role in antibody production… 
Highly Cited
2013
Highly Cited
2013
Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B… 
2013
2013
Introduction CC-292, an oral, highly selective, small-molecule irreversible-inhibitor of Btk is under investigation for the… 
Review
2013
Review
2013
Constitutive or aberrant signalling of the B cell receptor signalling cascade has been implicated in the propagation and…